GlassScriptPhysician profile
Brian Alexander Wolf
NPI 1407247307
$12,980.43
in general payments reported to CMS, 2019-2025
57 companies · $3,275 in 2025
The $3,275 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $1,181 · 2021: $1,028 · 2022: $1,259 · 2023: $2,100 · 2024: $2,754 · 2025: $3,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,113 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,112.74 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,441.17 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $1,058.39 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Catalyst Pharmaceuticals, INC. | $1,003.71 | 2019-2025 | |
| Sk Life Science, INC. | $814.09 | 2020-2025 | |
| Ge Healthcare | $645.43 | 2019-2025 | |
| Eisai INC. | $530.69 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $421.08 | 2020-2025 | Ingrezza, Ongentys |
| Neuropace, INC. | $387.99 | 2019-2025 | |
| Amgen INC. | $376.34 | 2019-2025 | Uplizna |
| Sunovion Pharmaceuticals INC. | $369.56 | 2019-2021 | |
| Pfizer INC. | $359.82 | 2023-2025 | |
| Neurelis, INC. | $332.35 | 2021-2025 | Valtoco |
| Livanova USA, INC. | $321.31 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $281.03 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $247.96 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $222.19 | 2019-2020 | |
| Acorda Therapeutics, INC | $208.17 | 2019-2024 | Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $207.31 | 2021-2025 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $176.55 | 2019-2020 | |
| Argenx US, INC. | $163.46 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Alnylam Pharmaceuticals INC. | $162.79 | 2019-2025 | Onpattro |
| Acadia Pharmaceuticals INC | $161.29 | 2019-2025 | Daybue, Nuplazid |
| Biohaven Pharmaceuticals, INC. | $149.82 | 2020-2021 | |
| Medtronic, INC. | $144.60 | 2025 | Percept PC Brainsense |
| Kyowa Kirin, INC. | $138.76 | 2020-2025 | Nourianz |
| Merz Pharmaceuticals, LLC | $122.44 | 2023-2025 | Xeomin, Inbrija |
| Amneal Pharmaceuticals LLC | $119.62 | 2019-2024 | Rytary, Ongentys |
| Lundbeck LLC | $97.30 | 2021-2024 | Vyepti |
| Csl Behring | $95.37 | 2022-2024 | Hizentra |
| Lilly USA, LLC | $93.18 | 2022-2025 | Amyvid, Emgality, Kisunla |
| Tanabe Pharma America, INC. | $86.53 | 2019-2025 | Radicava |
| Bioventus LLC | $83.20 | 2021 | |
| Corium, LLC | $72.82 | 2022-2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $72.44 | 2023-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $70.84 | 2019 | |
| Biogen, INC. | $62.96 | 2021-2023 | Spinraza |
| Jazz Pharmaceuticals INC. | $61.67 | 2024-2025 | |
| Allergan, INC. | $51.86 | 2020-2022 | |
| Adamas Pharmaceuticals, INC. | $51.17 | 2019-2020 | |
| Axsome Therapeutics, INC. | $49.38 | 2025 | Symbravo |
| Horizon Therapeutics Plc | $46.22 | 2022-2023 | Uplizna |
| Janssen Biotech, INC. | $43.35 | 2025 | |
| Mdd US Operations, LLC | $37.55 | 2023-2024 | Gocovri, Gocovri |
| Astrazeneca Pharmaceuticals LP | $37.28 | 2021-2024 | Andexxa |
| Amylyx Pharmaceuticals, INC. | $34.49 | 2023 | Relyvrio |
| Avion Pharmaceuticals | $33.86 | 2023 | Dhivy |
| Sumitomo Pharma America, INC. | $30.28 | 2023 | Aptiom |
| Akcea Therapeutics, INC. | $29.39 | 2020 | |
| Aucta Pharmaceuticals, INC. | $25.74 | 2025 | Motpoly Xr |
| Bausch Health US, LLC | $23.74 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.38 | 2022 | |
| Nevro Corp. | $19.05 | 2023 | Senza |
| Amicus Therapeutics, INC. | $18.85 | 2024 | Pombiliti, Opfolda |
| Genentech USA, INC. | $18.64 | 2023 | Polivy |
| Biohaven Pharmaceutical Holding Company LTD. | $16.60 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.86 | 2022 | |
| Zyla Life Sciences, INC. | $14.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.